FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market


13 February 2020 - Potential risk of cancer outweighs the benefits.

The U.S. FDA has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. 

The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.

Read FDA Statement

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Withdrawal